Lyra Therapeutics (LYRA) Retained Earnings (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Retained Earnings of -$433.7 million in Q4 2025, down 1.63% on a QoQ basis from -$426.8 million in Q3 2025, and down 7.14% YoY from -$467.1 million in Q4 2024.
Lyra Therapeutics (LYRA) Retained Earnings (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Retained Earnings for 7 consecutive years, with -$433.7 million the latest figure, recorded in Q4 2025.
- Retained Earnings for Q4 2025 came in at -$433.7 million, down 7.14% year-over-year; the trailing twelve-month figure through Dec 2025 was -$433.7 million (down 7.14% YoY), and the FY2025 annual result was -$433.7 million, down 7.14% from the prior year.
- Retained Earnings for Q4 2025 stood at -$433.7 million, down from -$426.8 million in the prior quarter.
- The five-year high for Retained Earnings was $25000.0 in Q1 2024, with the low at -$433.7 million in Q4 2025.
- A 5-year average of -$221.6 million and a median of -$212.5 million in 2022 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 3113650.0% in 2023 and jumped 385.71% in 2024, its largest moves.
- Lyra Therapeutics' Retained Earnings stood at -$193.4 million in 2021, then soared by 100.01% to $10000.0 in 2022, then sank by 3113650.0% to -$311.4 million in 2023, then tumbled by 30.01% to -$404.8 million in 2024, then declined by 7.14% to -$433.7 million in 2025.
- The last three Retained Earnings figures came in at -$433.7 million (Q4 2025), -$426.8 million (Q3 2025), and -$420.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -433.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -433.70 Mn |
| Sep 30, 2025 | -426.76 Mn |
| Jun 30, 2025 | -420.77 Mn |
| Mar 31, 2025 | -413.30 Mn |
| Dec 31, 2024 | -404.79 Mn |
| Sep 30, 2024 | 20,000.00 |
| Jun 30, 2024 | -381.90 Mn |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | -311.36 Mn |
| Sep 30, 2023 | -7,000.00 |
| Jun 30, 2023 | -280.55 Mn |
| Mar 31, 2023 | -12,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Sep 30, 2022 | -234.44 Mn |
| Jun 30, 2022 | -219.67 Mn |
| Mar 31, 2022 | -205.31 Mn |
| Dec 31, 2021 | -193.40 Mn |
| Sep 30, 2021 | -179.80 Mn |
| Jun 30, 2021 | -168.73 Mn |
| Mar 31, 2021 | -157.69 Mn |